The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis

被引:77
作者
Chen, Chuang [1 ,2 ,3 ]
Xia, He-Shun [4 ]
Gong, Yi-Ping [5 ]
Peng, Jun [6 ,7 ]
Peng, Chun-Wei [1 ,2 ,3 ]
Hu, Ming-Bai [1 ,2 ,3 ]
Zhu, Xiao-Bo [8 ,9 ]
Pang, Dai-Wen [6 ,7 ]
Sun, Sheng-Rong [10 ]
Li, Yan [1 ,2 ,3 ]
机构
[1] Wuhan Univ, Dept Oncol, Zhongnan Hosp, Wuhan 430071, Peoples R China
[2] Hubei Key Lab Tumor Biol Behav, Wuhan 430071, Peoples R China
[3] Hubei Canc Clin Study Ctr, Wuhan 430071, Peoples R China
[4] Hubei Canc Hosp, Dept Pathol, Wuhan 430079, Hubei, Peoples R China
[5] Hubei Canc Hosp, Dept Breast Surg, Wuhan 430079, Hubei, Peoples R China
[6] Wuhan Univ, Coll Chem & Mol Sci, Key Lab Analyt Chem Biol & Med, Minist Educ, Wuhan 430072, Peoples R China
[7] Wuhan Univ, State Key Lab Virol, Wuhan 430072, Peoples R China
[8] Wuhan Jiayuan Quantum Dots Co Ltd, Wuhan 430074, Peoples R China
[9] Wuhan Tumor Nanometer Diag Engn Res Ctr, Wuhan 430074, Peoples R China
[10] Wuhan Univ, Dept Breast & Thyroid Surg, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
Quantum dots; Breast carcinoma; HER2; Tumor heterogeneity; Quantitative determination; Survival analysis; PREDICTIVE MARKER; EXPRESSION; TISSUE; TRASTUZUMAB; THERAPY; CLASSIFICATION; ONCOLOGY; RECEPTOR; SHOWS; IMMUNOFLUORESCENCE;
D O I
10.1016/j.biomaterials.2010.07.091
中图分类号
R318 [生物医学工程];
学科分类号
100103 [病原生物学];
摘要
Accurate classification is fundamental for breast cancer (BC) personalized care. Current BC classification based on the either traditional morphological staging or molecular signatures seems inefficient to reveal the "true" behaviors of invasive BC evolution. An appropriate approach combining the macro- and micro-pathologic information might be more useful academically as well as clinically. Here we explore a holistic approach by integrating a key molecular prognostic indicator of BC, HER2, with quantitative determination using quantum dots (QDs)-based nanotechnology and spectral analysis, and a key macro-pathologic indicator, tumor size, resulting a new indicator, total HER2 load. This indicator might better reveal BC heterogeneity and new subtypes of BC with different 5-year disease-free survival compared with current methods, which could be helpful in formulating a more personalized targeted therapy for BC. Furthermore, this mode integrating macro- and micro-pathological indicators might help gain new insights into invasive BC biological behaviors. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:8818 / 8825
页数:8
相关论文
共 43 条
[1]
The HER2 testing conundrum [J].
Allison, Malorye .
NATURE BIOTECHNOLOGY, 2010, 28 (02) :117-119
[2]
Camp RL, 2003, CANCER RES, V63, P1445
[3]
Automated subcellular localization and quantification of protein expression in tissue microarrays [J].
Camp, RL ;
Chung, GG ;
Rimm, DL .
NATURE MEDICINE, 2002, 8 (11) :1323-1327
[4]
Chen C.L., 2010, Nanotechnology, V21
[5]
Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer [J].
Chen, Chuang ;
Peng, Jun ;
Xia, He-Shun ;
Yang, Gui-Fang ;
Wu, Qjong-Shui ;
Chen, Liang-Dong ;
Zeng, Li-Bo ;
Zhang, Zhi-Ling ;
Pang, Dai-Wen ;
Li, Yan .
BIOMATERIALS, 2009, 30 (15) :2912-2918
[6]
The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis [J].
Chen, Liang-Dong ;
Liu, Jia ;
Yu, Xue-Feng ;
He, Man ;
Pei, Xiao-Feng ;
Tang, Zhao-You ;
Wang, Qu-Quan ;
Pang, Dai-Wen ;
Li, Yan .
BIOMATERIALS, 2008, 29 (31) :4170-4176
[7]
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers [J].
Chia, Stephen ;
Norris, Brian ;
Speers, Caroline ;
Cheang, Maggie ;
Gilks, Blake ;
Gown, Allen M. ;
Huntsman, David ;
Olivotto, Ivo A. ;
Nielsen, Torsten O. ;
Gelmon, Karen .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5697-5704
[8]
Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis [J].
Choi, Y. H. ;
Ahn, J. H. ;
Kim, S. -B. ;
Jung, K. -H. ;
Gong, G. -Y. ;
Kim, M. -J. ;
Son, B. -H. ;
Ahn, S. -H. ;
Kim, W. K. .
ANNALS OF ONCOLOGY, 2009, 20 (08) :1337-1343
[9]
New Molecular Classifications of Breast Cancer [J].
Cianfrocca, Mary ;
Gradishar, William .
CA-A CANCER JOURNAL FOR CLINICIANS, 2009, 59 (05) :303-313
[10]
The Global Breast Cancer Disparity Strategies for Bridging the Gap [J].
de Souza, Jonas A. ;
Bines, Jose .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (23) :2589-2590